PPAR Agonists: Potential as Therapeutics for Neovascular Retinopathies
Figure 3
Schematic
diagram of the mechanisms of PPAR action. In the unliganded state (top), the PPAR
receptor exists as a heterodimer with the RXR nuclear receptor and the
heterodimer is located on a PPAR response element (PPRE) of a target gene. The
unliganded receptor heterodimer complex is associated with a multicomponent
corepressor complex, which physically interacts with the PPAR receptor through
silencing mediator for retinoid and thyroid hormone receptors (SMRT). The
corepressor complex contains histone deacetylase (HDAC) activity, and the
deacetylated state of histone inhibits transcription. After PPAR ligand
binding, the corepressor complex is dismissed, and a coactivator complex is
recruited to the heterodimer PPAR receptor (bottom). The coactivator complex
contains histone acetylase activity, leading to chromatin remodeling,
facilitating active transcription. (Adapted with permission from: J. M. Olefsky, “Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.” Journal of Clinical Investigation, vol. 106, no. 4, pp. 467-472, 2000); C. K. Glass, M. G. Rosenfeld, “The coregulator exchange in transcriptional functions of nuclear receptors”. Genes & Development,vol. 14, no. 2, pp. 121-141, 2000.)